Sensorion Appoints Peter Weber as Chief Medical Officer

Dr. Weber has more than 20 years of experience in hearing loss treatment and medical leadership. He specialises in rare genetic ear disorders and has led the clinical development of gene therapies for genetic hearing loss.

Before joining Sensorion, Dr. Weber served as Chief Medical Officer at Decibel Therapeutics and later as a Senior Medical Consultant to Regeneron. At Decibel, he also led a programme to prevent hearing loss caused by chemotherapy.

Read More:Ensono Appoints Ayush Mittal as Senior Vice President

Most recently, Dr. Weber was Chief Medical Officer at Auregen BioTherapeutics, where he led an early-stage clinical trial of a 3D-printed cartilage implant to treat microtia, a condition that affects the development of the outer ear in children. He also helped secure Orphan Drug and Breakthrough Therapy designations for the treatment.

Peter Weber, MD, MBA, said: “Having worked on some of the first gene therapies for genetic forms of hearing loss, including otoferlin-related hearing loss, I have seen what these treatments can mean for children and their families. I have also seen how quickly the field has matured.

Frédéric Chereau, Chief Executive Officer of Sensorion, said: “We are delighted to welcome Peter to Sensorion as we advance SENS-601 into the clinic. Peter combines decades of hands-on clinical practice in otology and neurotology with direct experience leading gene therapy programs for hearing loss, including otoferlin-related hearing loss. Few people have taken inner-ear gene therapy from the clinic toward approval.

About Sensorion

Founded in 2009, Sensorion is a biotechnology company developing treatments to restore hearing and prevent hearing loss. The company uses its research, and technology platform to better understand inner ear diseases and develop potential treatments.

Read More:Yoodli Appoints Mike Mather as Chief Learning Advisor